InduPro develops proximity-based therapeutics by manipulating the spatial relationships of cell surface proteins. The company utilizes proprietary platforms to design novel ways to induce proximity, enabling new biology for drug development. This science focuses on creating new medicines by controlling protein interactions on the cell surface.
Funding
Funding not disclosed
Founders
Product
Problem
Current protein therapies often lack precise targeting and efficacy due to the complex spatial relationships of proteins on cell surfaces. Understanding and manipulating these protein interactions remains a challenge, hindering the development of more effective treatments.
Solution
InduPro is developing a cell-surface platform technology that manipulates protein interactions through spatial proximity to enhance the efficacy of protein-based therapeutics. Their approach focuses on defining the role of spatial relationships in biology and designing methods to induce proximity between proteins on the cell surface. InduPro leverages both inherent and induced proximity to modulate disease biology, creating opportunities for next-generation therapeutics. The company's Membrane Interactomics (MInt) database identifies novel targets and co-target pairings, while their ARRIS platform uses multi-specific antibody technology to bring together two proteins at the cell surface. InduPro's therapeutic engineering capabilities enable the development of robust clinical molecules that address unmet medical needs.
Target Audience
InduPro's primary customers are pharmaceutical companies and research institutions focused on developing protein therapeutics and exploring new approaches to modulate disease biology through protein interactions.
Features
- Membrane Interactomics (MInt) database: Identifies novel targets and co-target pairings across a wide spectrum of diseases.
- Proximity Modalities (ARRIS) platform: Uses multi-specific antibody technology to bring together two proteins at the cell surface.
- Therapeutic engineering: Internal antibody discovery and engineering capabilities with protein characterization and optimization tools.
- End-to-end approach: Includes binder creation, application identification, target discovery, and clinical molecule delivery.